Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN versus XALATAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN versus XALATAN.
TRAVATAN vs XALATAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix in the ciliary body.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is approximately 45 minutes for travoprost acid (active metabolite). Clinical context: due to rapid systemic clearance, ocular hypotensive effect persists for 24 hours from corneal tissue binding.
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
Renal (primarily as metabolites): ~70%; Fecal: ~25%; Unchanged drug in urine: <1%
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog